WO2025242216 - INDOLINE COMPOUNDS AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/242216
Publication Date
27.11.2025
International Application No.
PCT/CN2025/096909
International Filing Date
23.05.2025
Title **
[English]
INDOLINE COMPOUNDS AND USE THEREOF
[French]
COMPOSÉS INDOLINES ET LEUR UTILISATION
[Chinese]
吲哚啉类化合物及其用途
Applicants **
HANGZHOU BAICREAT PHARMA-TECH CO., LTD.
Inventors
ZHANG, Fengmin
LEI, Chong
Priority Data
202410656974.9
24.05.2024
CN
202411014650.1
26.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2272 | |
| EPO | Filing, Examination, Granting | 16385 | |
| Japan | Filing, Examination, Granting | 2400 | |
| South Korea | Filing, Examination, Granting | 2594 | |
| USA | Filing, Examination, Granting | 5140 |
Total:
28,791
Contact Us
Abstract[English]
The present invention relates to a class of indoline compounds, and particularly relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in treating a related disease. Further disclosed are a preparation method for the indoline compounds and pharmaceutical use thereof. The indoline compounds can be used as a PTPN2/PTPN1 inhibitor for treating diseases related to PTPN2/PTPN1 signal pathway-mediated abnormal expression (including but not limited to tumors).[French]
La présente invention concerne une classe de composés indolines, et concerne en particulier l'utilisation d'un composé représenté par la formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci dans le traitement d'une maladie associée. L'invention concerne en outre un procédé de préparation des composés indolines et une utilisation pharmaceutique de ceux-ci. Les composés indolines peuvent être utilisés en tant qu'inhibiteur de PTPN2/PTPN1 pour le traitement de maladies associées à l'expression anormale médiée par la voie du signal de PTPN2/PTPN1 (y compris, mais sans caractère limitatif, les tumeurs). .[Chinese]
涉及一类吲哚啉类化合物，具体涉及式(I)所示化合物或其药学上可接受的盐在制备治疗相关疾病中的应用；进一步，还公开了该类吲哚啉类化合物的制备方法及其制药用途，所述吲哚啉类化合物可作为PTPN2/PTPN1抑制剂用于治疗介导PTPN2/PTPN1信号通路异常表达相关的疾病(包括但不限于肿瘤)。